Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists - Wikidata - wikimedia - TriplyDB

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

http://www.wikidata.org/entity/Q35605635

about

Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.How tumour necrosis factor blockers interfere with tuberculosis immunity.Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents.Understanding latent tuberculosis: a moving target.Psoriatic disease and tuberculosis nowadays.Cellular and humoral mechanisms involved in the control of tuberculosis Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists Anti-arthritic property of crude extracts of Piptadeniastrum africanum (Mimosaceae) in complete Freund's adjuvant-induced arthritis in rats.Anti-inflammatory effects of royal jelly on ethylene glycol induced renal inflammation in rats Tumor necrosis factor inhibitors and infection complications.Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina.Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy.Screening for tuberculosis infection prior to initiation of anti-TNF therapy.Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans Infliximab in the treatment of rheumatoid arthritis IFN-gamma release assays in tuberculosis management in selected high-risk populations.Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients.The in vivo immunomodulatory effect of recombinant tumour necrosis factor-alpha in guinea pigs vaccinated with Mycobacterium bovis bacille Calmette-Guérin.Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry.Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies Multi-functional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists.Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test.The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.TNF-alpha antagonist therapy modify the tuberculin skin test response.Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study.Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases.Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents IFN-γ-release assays to diagnose TB infection in the immunocompromised individual

P2860

Q30412650-B1CA4357-F1C6-497B-8AE5-9FDDBB1FE02D Q33625128-BFFDF220-F900-4AA0-B800-A5E5BCF732A6 Q34065405-97FF8757-ABCC-4E94-BD7E-BF6770EC2DFE Q34152994-73DF0C96-4440-4239-B3BA-C001862A7D64 Q34660051-70BE7F58-AEFB-4758-9066-3AF72F9D6832 Q35230204-F5457D7C-555F-422E-83B4-E7CEBA5EBD9A Q35300301-7501C538-8972-43B7-BCC1-29482926B45C Q35851626-FAE8C37A-9DDA-4834-8634-08234B56D148 Q35974892-906EE38A-AAF9-4D3B-99E8-19AEFDA9A2F8 Q35996521-D17A8638-2E6B-4B1A-B1B8-10F60017782A Q36246140-75643F4A-61BF-4889-921B-C23B4C5402B1 Q36281697-05988EDE-B36E-4C23-8074-DE417B46AE39 Q36589311-A4E60D45-71F6-434B-B7F3-CEAE2469B18B Q36806922-CECD9B75-5E39-4313-9CD0-C1E50169AE8B Q36846629-1760227F-D26F-43D9-B196-E45B696DD378 Q36923535-727FD2CD-683A-455E-910D-DA18F45F7535 Q36995803-573F201F-02CF-47AE-936D-03A447C260FF Q37170834-AC86C1B6-157B-472B-AF75-928887DF9D25 Q37303230-780A4199-267C-49E9-9792-83A134705BE7 Q37418061-96FA1051-D114-43DB-B3FF-E76C7F221CD1 Q38102726-14DD84D0-741C-422D-9814-B473F2BD85D6 Q38462400-CB20FC4E-7D12-46EA-990F-B7B5C651AB92 Q39753551-D41B03D9-EEDB-453B-9945-9B630EC3CCB1 Q40680333-6591F126-4148-4692-A90C-295B72DC6264 Q41658983-532B2067-5CB7-4B43-8049-B91B6074A2FE Q42014279-70695E03-98CC-4210-9598-4064D3F9B489 Q42073430-EC6E0505-F696-47E7-B8CB-D11227AD77CF Q42228424-83E42634-BDFC-4BAB-B8CE-2C1D58F9F76B Q42252749-8E67B668-BD5C-4613-A002-3CE4957F0E9A Q45942161-2988F3E3-895F-46F1-A7CE-24976C501959 Q46165734-5EAF530E-8244-498C-80C7-F5B6307A9BF4 Q47561672-CB1EB8E9-D98E-44D1-AF40-67716F134BA1 Q51574799-72D3FD3D-D3A3-40AC-A2BD-47B6C09E0EE3 Q54917641-2150C414-BE2C-4425-A6C1-AFCB48E14C6A Q55305483-D181C799-BEA3-4CC5-955A-5C070C087313 Q58480211-32EDA2A7-0327-4E05-A6BC-7E5C856D7AE0 Q58924849-4719C78E-A590-4BF1-BDAC-399704CECD1E

P2860

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

http://www.wikidata.org/entity/Q35605635

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@ast

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@en

type

label

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@ast

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@en

prefLabel

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@ast

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@en

P1433

Q35605635-10F731A6-01F0-4F64-864E-4DC9A1197960

P1476

Q35605635-9EADC951-5B5B-485C-8C1E-102B4D0DF6C8

P2093

Q35605635-20F049FD-A877-4BFD-8915-AB298B04446B

Q35605635-2F90B77C-AFC0-48FE-8882-F0858E1C7862

Q35605635-4368203A-A571-4E47-B314-77E7A53913E6

Q35605635-51343DEF-EC34-405B-8932-8F69A18DF69A

Q35605635-56CE64F5-3D6D-4DC3-8821-4252B30C08DA

Q35605635-6E7AB379-A264-4A7B-B516-D86D5F5946CD

Q35605635-982E7322-18B1-48C7-893D-DEC253142043

Q35605635-A7F664E8-B4B7-47A8-BF78-21CBB8549086

Q35605635-BABAD022-F376-4DC4-9D58-A11F9638F722

Q35605635-C38036C6-7F0A-46B1-9089-BD19318A77A0

P2860

Q35605635-03AB22CD-09F2-4B20-8CD3-F05BC1DE4649

Q35605635-09E26C34-1F6C-4588-8F49-A8B6706906E5

Q35605635-0D88F008-CAB0-439F-9A4E-BD4B6C2995CB

Q35605635-0FC21BAE-E37F-4A36-8762-0EEB7BF61645

Q35605635-19E7EAE6-CDD0-453C-A1D6-4BB8B9CBDF92

Q35605635-1B4DDE07-E55D-4C1E-BCE2-4695A640A092

Q35605635-1EA27EFA-ABBE-4672-A048-03534DDA979C

Q35605635-219160EB-9AE9-4D4C-BEA4-ACAE103CFB5A

Q35605635-29049020-4CD8-4400-9ADB-0D87D559A2D6

Q35605635-2CD1304E-3C7E-4A92-AC5C-783292F4AFB7

P2888

Q35605635-22BCBA69-38B2-4F7C-A327-AE45266DF445

P304

Q35605635-68AEB69B-B1CC-4371-8DCB-CADE9D1C381C

P31

Q35605635-A678447C-23A9-423E-AF9E-4BD230C96B6F

P356

Q35605635-6666F07D-D76B-47DE-951C-1F46A0CCEF28

P433

Q35605635-756BBE9E-F06C-455E-8338-4C8D598F44D0

P478

Q35605635-A2D554CF-7772-4AC8-BDBC-5A21F9D4326B

P50

Q35605635-8A49E528-F4B2-4437-9EF0-D5990C18C096

Q35605635-8BCDA0CC-928C-45BF-8D4B-3E30056FCAF9

Q35605635-995C6170-E0C8-4F7B-B749-C9364169A6A3

P577

Q35605635-4F7D1BE0-F7D2-45EE-9AB0-84CA97B6DA28

P5875

Q35605635-F8DEF58F-F987-4DCD-9E60-F87F486606BC

P6179

Q35605635-A4F9BF4E-2347-4193-A2A8-DFA62C6C98DB

P698

Q35605635-1285BA14-DE0E-4CC7-BCB9-7E7CE0B25F4F

P921

Q35605635-31FFC8C3-A9B6-472B-A853-1946B3F48385

Q35605635-4c1aa895-d6dd-4ba2-9050-7892ffcc51ef

Q35605635-85A54ABD-C384-4159-80D3-7C5A173FD915

P932

Q35605635-D89CAE34-4641-4C32-ABF0-99DC8E9856FC

P356

P1433

Arthritis Research and Therapy

P1476

Inhibition of anti-tuberculosi ...... ur necrosis factor antagonists

@en

P2093

Abdul Monem Hamid

http://www.w3.org/2001/XMLSchema#string

Dominique Emilie

http://www.w3.org/2001/XMLSchema#string

Dominique Salmon

http://www.w3.org/2001/XMLSchema#string

Francis Berenbaum

http://www.w3.org/2001/XMLSchema#string

Gabriel Baron

http://www.w3.org/2001/XMLSchema#string

Haïfa Hamdi

http://www.w3.org/2001/XMLSchema#string

Jean-Charles Delchier

http://www.w3.org/2001/XMLSchema#string

Karin Weldingh

http://www.w3.org/2001/XMLSchema#string

Marc Lemann

http://www.w3.org/2001/XMLSchema#string

Maria-Victoria Prejean

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10)

Central memory and effector memory T cell subsets: function, generation, and maintenance

B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis

Specific immune-based diagnosis of tuberculosis.

Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells.

Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak.

Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection.

A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements

P2888

P304

R114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR1994

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Xavier Puéchal

Bertrand Dautzenberg

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6925593

http://www.w3.org/2001/XMLSchema#string

P6179

1001244816

http://www.w3.org/2001/XMLSchema#string

P698

16859506

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

1779425

http://www.w3.org/2001/XMLSchema#string